MSD’s monoclonal antibody, indicated for 15 types of cancer, smashed industry records with sales of $27.3 billion in 2024, ...

Michelle Xia represents a rising generation of biotech companies in China challenging Western giants.

By Michael Erman NEW YORK (Reuters) -Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the U.S. on October 1, ...

Merck has filed a petition with the U.S. Patent and Trademark Office to challenge seven of Halozyme’s patents. Halozyme said ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

The therapy also reduced the amount of time patients spend receiving chemotherapy treatment by 49.7% compared with IV ...

Merck’s new formulation of the mega-blockbuster Keytruda, made in collaboration with Alteogen, could help to keep the drug’s patent cliff at bay.

Recent market volatility notwithstanding, equities generally deliver solid returns over long periods, like a decade. The key ...

A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on ...

Most people receive Keytruda infusions for up to 2 years. But in some cases, treatment may last longer if there’s evidence that the drug is still effective and the side effects are minimal.

MSD’s subcutaneous (SC) Keytruda (pembrolizumab) has shown non-inferior pharmacokinetics (PK) to the intravenous (IV) version of the company’s blockbuster therapy in a pivotal trial.